Group 1 - CXO concept stocks have shown significant gains, with WuXi AppTec (02268) rising by 7.97% to HKD 63, WuXi Biologics (02269) increasing by 4.7% to HKD 40.08, WuXi PharmaTech (603259) (02359) up by 2.28% to HKD 19.7, and Kanglong Chemical (300759) (03759) also up by 2.28% to HKD 19.7 [1] - According to a report from Citi, investor focus is shifting from AI-enabled industries to AI replacing intermediaries, with a clearer positive impact expected on Contract Research, Development, and Manufacturing Organizations (CRDMO) compared to the mixed effects on Contract Research Organizations (CRO) due to internal AI adoption by pharmaceutical companies [1] - The report indicates that the recent decline in the sector is not driven by fundamentals but rather by position adjustments and capital flows, suggesting that the current pullback is a technical/short-term fluctuation rather than a deterioration in demand or execution [1] Group 2 - The report highlights that leading companies in the industry may experience overselling during this market window lacking catalysts, creating attractive entry points for investors with a 3 to 12-month investment horizon [1]

每经AI快讯，2月27日，港股CXO概念股涨幅居前，药明合联(02268.HK)涨7.97%，报63港元；药明生 物(02269.HK)涨4.7%，报40.08港元；药明康德(02359.HK)涨2.28%，报19.7港元；康龙化成(03759.HK) 涨2.28%，报19.7港元。 ...

Group 1 - The core viewpoint of the article highlights the recent performance of CXO concept stocks, with notable gains in companies such as WuXi AppTec (02268) up 7.97% to HKD 63, WuXi Biologics (02269) up 4.7% to HKD 40.08, WuXi PharmaTech (02359) up 2.28% to HKD 19.7, and Kanglong Chemical (03759) also up 2.28% to HKD 19.7 [1] - According to a report from Citi, the focus of investors is shifting from AI-enabled industries to AI replacing intermediaries, with a clearer positive impact expected on Contract Research, Development, and Manufacturing Organizations (CRDMO) compared to the mixed effects on Contract Research Organizations (CRO) due to the accelerated adoption of AI by pharmaceutical companies [1] - The report indicates that the recent decline in the sector is not driven by fundamentals but rather by position adjustments and capital flows, suggesting that the current pullback is a technical/short-term fluctuation rather than a deterioration in demand or execution [1] Group 2 - The report emphasizes that leading companies in the industry may experience overselling during this market window lacking catalysts, creating more attractive entry points for investors with a 3 to 12-month investment horizon [1]

该行认为，公司是药物研发业务的全球领导者，正随着中国CRO行业的增长趋势发展；集团在维持药 物研发领导地位同时，亦正扩展至下游的后期临床开发和商业化生产，并涉足生物制剂领域。 康龙化成（300759）(03759)涨超3%，截至发稿，涨2.6%，报19.76港元，成交额1900.2万港元。 花旗发布研报称，对康龙化成展开为期90天的正面催化观察，主要催化剂为公司即将公布2025年全年业 绩、订单增长加速公司今年的指引更乐观。报告指出，公司将成为客户需求复苏的领先指标，并为未来 收入增长提供更清晰指引，可能导致今财年指引高于市场共识，并推动股价正面重估。花旗对公司今年 每股盈利的预测较市场共识高出4%。 ...

花旗发布研报称，对康龙化成展开为期90天的正面催化观察，主要催化剂为公司即将公布2025年全年业 绩、订单增长加速公司今年的指引更乐观。报告指出，公司将成为客户需求复苏的领先指标，并为未来 收入增长提供更清晰指引，可能导致今财年指引高于市场共识，并推动股价正面重估。花旗对公司今年 每股盈利的预测较市场共识高出4%。 该行认为，公司是药物研发业务的全球领导者，正随着中国CRO行业的增长趋势发展；集团在维持药 物研发领导地位同时，亦正扩展至下游的后期临床开发和商业化生产，并涉足生物制剂领域。 智通财经APP获悉，康龙化成(03759)涨超3%，截至发稿，涨2.6%，报19.76港元，成交额1900.2万港 元。 ...

(本文来自第一财经) 百济神州跌超8%，药明生物跌超7%，泰格医药、康龙化成跌超5%，君实生物、药明康德、诺诚健华等 跟跌。 ...

Core Insights - The China Securities Medicine and Medical Device Innovation Index (931484) shows mixed performance among its constituent stocks, with New and Achieve leading the gains at 3.63% [1] - The Medical Innovation ETF (516820) has seen a net inflow of 12.6971 million yuan over the past three days, with a peak single-day inflow of 6.1732 million yuan [1] - The current phase of brain-computer interface technology is described as an explosive period, with multiple countries, including China, accelerating their strategic positioning in global brain science [1] - AI is transitioning from a supportive role to becoming a core driver of value reconstruction and efficiency revolution in the medical industry, impacting various sectors such as medical imaging and drug development [1] Industry Overview - The Medical Innovation ETF closely tracks the China Securities Medicine and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]

该行认为集团是药物研发业务的全球领导者，正乘着中国CRO行业的增长趋势发展;集团在维持药物研 发领导地位同时，亦正扩展至下游的后期临床开发和商业化生产，并涉足生物制剂领域。 花旗指，集团将成为客户需求复苏的领先指标，并为未来收入增长提供更清晰指引，可能导致今财年指 引高于市场共识，并推动股价正面重估。花旗对集团今年每股盈利的预测较市场共识高出4%。 花旗发布研报称，对康龙化成（300759）(03759)展开为期90天的正面催化观察，主要催化剂为集团即 将公布去年全年业绩、订单增长加速下集团今年的指引更乐观。花旗予康龙化成H股"买入"评级，目标 价45港元. ...

花旗指，集团将成为客户需求复苏的领先指标，并为未来收入增长提供更清晰指引，可能导致今财年指 引高于市场共识，并推动股价正面重估。花旗对集团今年每股盈利的预测较市场共识高出4%。 该行认为集团是药物研发业务的全球领导者，正乘着中国CRO行业的增长趋势发展; 集团在维持药物研 发领导地位同时，亦正扩展至下游的后期临床开发和商业化生产，并涉足生物制剂领域。 智通财经APP获悉，花旗发布研报称，对康龙化成(03759)展开为期90天的正面催化观察，主要催化剂为 集团即将公布去年全年业绩、订单增长加速下集团今年的指引更乐观。花旗予康龙化成H股"买入"评 级，目标价45港元. ...

花旗予康龙化成H股"买入"评级，目标价为45港元；认为集团是药物研发业务的全球领导者，正乘着中 国CRO行业的增长趋势发展；集团在维持药物研发领导地位同时，亦正扩展至下游的后期临床开发和 商业化生产，并涉足生物制剂领域。 花旗发表研报指，对康龙化成展开为期90天的正面催化观察，主要催化剂为集团即将公布去年全年业 绩、订单增长加速下集团今年的指引更乐观。花旗指，集团将成为客户需求复苏的领先指标，并为未来 收入增长提供更清晰指引，可能导致今财年指引高于市场共识，并推动股价正面重估。 ...